Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale

Nosheen Nasir 1, Faisal Mahmood 2, Kiren Habib 3, Iffat Khanum 3, Bushra Jamil 4

1. Internal Medicine, Aga Khan University, Karachi, PAK 2. Internal Medicine, Aga Khan University Hospital, Karachi, PAK 3. Medicine, Aga Khan University, Karachi, PAK 4. Medicine/Infectious Diseases, Aga Khan University Hospital, Karachi, PAK

Corresponding author: Nosheen Nasir, nosheen.nasir@aku.edu

Abstract

Introduction
Cytokine release syndrome in COVID-19 is characterized by hyperinflammation, which manifests as acute respiratory distress syndrome (ARDS), multiorgan failure, and high inflammatory parameters. Tocilizumab, an interleukin 6 (IL-6) antagonist has been used in COVID-19 ARDS with conflicting results from different parts of the world.

Objective
To study the treatment outcomes with tocilizumab in patients with COVID-19 ARDS and hyperinflammation using the World Health Organization (WHO) COVID-19 ordinal scale.

Methods
An observational study was conducted from Feb 2020 to May 2020 on COVID-19 ARDS patients with hyperinflammation.

Results
A total of 244 patients with COVID-19 were admitted, out of which 107 had ARDS. Thirty patients had both ARDS and hyperinflammation and received tocilizumab. The mean age was 62.5 years (SD: 13.5) and the majority were male (83%). The mean CRP pre-treatment was 217.5 mg/L and post 48 to 72 hours of tocilizumab treatment was 98.5 mg/L. Twenty-one patients (70%) also received concomitant intravenous (IV) methylprednisolone. Of the 30 patients, seven died and 20 recovered. Ten patients required intensive care unit admission and nine developed nosocomial infections. COVID-19-associated aspergillosis was diagnosed in three patients post tocilizumab treatment. Mortality was significantly higher in patients who developed a nosocomial infection and who required intermittent positive pressure ventilation (IPPV). Post-treatment, clinical improvement was observed in patients who had a median score of 5 on the WHO ordinal scale.

Conclusion
Our study supports the use of tocilizumab in COVID-19 ARDS patients with a pre-treatment median WHO ordinal severity score of 5 and recommends the monitoring of nosocomial infections and opportunistic infections.

Introduction
COVID-19 was announced as a pandemic by the World Health Organization (WHO) in March 2020 and since then it has infected 5,113,706 people globally and resulted in 330,361 deaths as of date [1-2]. The life-threatening manifestation of COVID-19 is acute respiratory distress syndrome (ARDS) and is associated with significant morbidity and mortality [3]. The underlying pathogenesis of ARDS involves a dysregulated immune response leading to a cytokine release syndrome (CRS), referring to an excessive and uncontrolled release of pro-inflammatory cytokines. CRS in COVID-19 is characterized by hyperinflammation, which manifests as ARDS, multiorgan failure, and high inflammatory parameters [4]. Key in the development of the CRS is an exaggerated release of the proinflammatory cytokine Interleukin-6 (IL-6) and elevated IL-6 levels correlate with ARDS [5]. Marked elevation of C-reactive protein (CRP) (whose expression is propelled by IL-6) also serves as a biomarker to assess the severity of clinical CRS [5] and studies have used CRP and ferritin as surrogate markers of hyperinflammation [6-7].
Given the pivotal role of IL-6, it has been postulated that targeting IL-6 with available IL-6 inhibitors like tocilizumab may lead to clinical suppression of the CRS [8]. Data from clinical studies have been conflicting with regards to the efficacy of tocilizumab in COVID-19 ARDS. While limited studies from China have shown improved outcomes in COVID-19 patients with hyperinflammation and ARDS [9], a study from Italy did not show significant mortality benefit [10]. While randomized controlled trials are awaited, there is an urgency to explore therapeutic options that can help to avert ICU admissions, especially given the limited capacity in resource-constrained settings. Moreover, preliminary reports from the COVACTA trial (a study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia) by the manufacturer have not shown a mortality benefit with the use of this drug in COVID-19 [11]. Hence, we would like to report our clinical experience of the management of ARDS and hyperinflammation with the IL-6 inhibitor tocilizumab in patients with critical COVID-19.

A preprint of this article (Treatment of ARDS and hyperinflammation in COVID-19 with IL-6 antagonist tocilizumab: a tertiary care experience from Pakistan) is available [12].

Materials And Methods

We conducted an observational study on COVID-19 patients with ARDS and hyperinflammation admitted to a 700-bedded tertiary care hospital. A cytokine storm or hyperinflammation was defined as either serum CRP of ≥100 mg/L or ferritin of ≥900 ng/mL or both [6]. ARDS was defined as per the WHO definition as having "onset within 1 week of a known clinical insult or new or worsening respiratory symptoms, chest imaging (radiograph, CT scan, or lung ultrasound) with bilateral opacities, not fully explained by volume overload, lobar or lung collapse, or nodules and respiratory failure not fully explained by cardiac and PaO2/FIO2 <300 mmHg" [13]. As per hospital COVID-19 management guidelines, patients were considered for treatment with intravenous tocilizumab if they fulfilled the above-mentioned criteria for ARDS and hyperinflammation and if they failed treatment with steroids in the first 24 to 48 hours, that is, if the patient’s partial pressure of oxygen (PaO2/fraction of inspired oxygen (FiO2) ratio decreased further AND/OR the patient’s oxygen requirement worsened or immediately if they fulfilled criteria for septic shock and required mechanical ventilation. Patients were not given intravenous (IV) tocilizumab if they had any contraindication, such as hepatitis, as indicated by transaminitis (alanine transaminase (ALT) of greater than three times the upper normal limit) and/or ongoing bacterial infection or tuberculosis. A single dose was administered intravenously to all patients who met eligibility and in those in whom there was no improvement in terms of a) oxygen requirement, b) increased chest infiltrates on chest radiograph, or c) decreased PaO2/FiO2 ratio, another intravenous dose was repeated at 12 hours. Demographics and clinical data from the hospital medical records were collected using a structured proforma. The outcomes assessed included in-hospital mortality, length of stay, and the development of nosocomial infection during hospitalization. In order to assess response to treatment, the WHO ordinal scale ranging from 1 to 8 where a score of one means no mortality, length of stay, and the development of nosocomial infection during hospitalization. In order to explore therapeutic options that can help to avert ICU admissions, especially given the limited capacity in resource-constrained settings. Moreover, preliminary reports from the COVACTA trial (a study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia) by the manufacturer have not shown a mortality benefit with the use of this drug in COVID-19 [11]. Hence, we would like to report our clinical experience of the management of ARDS and hyperinflammation with the IL-6 inhibitor tocilizumab in patients with critical COVID-19.

Categorical variables, such as gender and the development of nosocomial infection, were described as proportions, and continuous variables like age and length of hospital stay were described using mean, median, and interquartile range (IQR) values. Proportions for categorical variables as mentioned above were compared using the χ² test or Fisher exact test where appropriate. Continuous variables were compared using the student’s t-test or Wilcoxon rank-sum test as appropriate. Statistical analysis was performed using STATA ver 12 (STATA Corp., College Station, Texas). A p-value of less than 0.05 was considered statistically significant.

Results

A total of 244 patients with COVID-19 were admitted from February 26 to May 15, 2020, out of which 107 met WHO criteria for ARDS. Of these, there were 30 patients with ARDS who also met the criteria for hyperinflammation and qualified to receive tocilizumab. The clinical characteristics and outcomes of these 30 patients are summarized in Table 1. The mean age was 62.5 years (SD: 13.5 years), and the majority were male (83%). None of the patients had a rheumatological illness. The median dose of IV tocilizumab was 600 mg (range: 320 – 680 mg). No adverse effects were observed during or post-infusion. Twenty-one patients (70%) also received concomitant systemic steroids (IV methylprednisolone at a dose of 40 mg twice daily for three to five days). Of the 30 patients, seven died and 20 recovered while information was missing on three patients who left against medical advice. The mean length of hospitalization was 12 days (SD: 6.7). The mean CRP pre- and post-tocilizumab treatments in those who died compared to those who survived are shown in Figure 1.
| Demographics                        |   |
|------------------------------------|---|
| Number patients (N)                | 30|
| Median age in years (IQR)          | 65 years (IQR: 55-72) |
| Gender n(%)                        |   |
| Male                               | 25 (83%) |
| Female                             | 5 (17%)  |
| Length of stay mean ±SD days       | 12 ±6.7 |

| Pre-treatment ventilator status    |   |
|------------------------------------|---|
| Assisted ventilation n(%)          |   |
| IPPV                                | 10 (33%) |
| NIV                                 | 14 (48%) |
| None                                | 6 (20%)  |

| Drug management                    |   |
|------------------------------------|---|
| Tocilizumab dose median (range) mg | 600 (320-680) |
| Concomitant steroids n(%)          | 21 (70%)  |

| Outcome                            |   |
|------------------------------------|---|
| Acute-phase reactant response      |   |
| Pre-tocilizumab                    |   |
| Post-tocilizumab                   |   |
| CRP mean ± SD mg/L                 | 217.5± 64.6 | 98.4 ±56.3 |

| Immunosuppression                  |   |
|------------------------------------|---|
| Nosocomial infection n(%)          | 9 (30%) |
| Aspergillus infection/colonization n(%) | 7 (24%)  |

| Final outcome                      |   |
|------------------------------------|---|
| Dead                               | 7 (23%) |
| Alive                              | 20 (66%) |
| Unknown                            | 3 (10%)  |

**TABLE 1: Clinical characteristics and outcomes of COVID-19 patients who received tocilizumab**

CRP: C-reactive protein
Ten patients required intensive care unit (ICU) admission and intermittent positive pressure ventilation (IPPV), whereas 14 patients were managed on non-invasive ventilation (NIV). Nine patients developed nosocomial infections, of which six were hospital-acquired pneumonia (three with multi-drug resistant (MDR) acinetobacter, two with MDR Pseudomonas (P.) aeruginosa, and one with methicillin-resistant Staphylococcus aureus (MRSA). Patients who developed MRSA infection were treated with IV vancomycin and those with MDR acinetobacter or P. aeruginosa were treated with IV meropenem and colistin. Additionally, seven patients also isolated Aspergillus species from their respiratory specimens. Of these seven, only three patients were diagnosed with COVID-19-associated aspergillosis (based on clinical and radiological worsening and improvement in response to treatment) while in the rest, the aspergillus was considered a colonizer. Mortality was higher in patients who developed a nosocomial infection (p-value: 0.005) and who required IPPV (p-value: 0.023). The median WHO severity score before tocilizumab was 5 (range 4-7). While there was no change in the median WHO severity score 48 hours after tocilizumab, there was an overall improvement at five days (or last follow-up) with a median score of 3.5 (range 3 to 8) (Figure 2).
Out of 30 patients who received tocilizumab, 18 showed an improvement of at least one point on the ordinal score at 48 hours and 12 did not show any clinical improvement from their baseline pre-treatment score. None of the patients showed progression on the ordinal score at 48 hours. However, when pre-treatment scores were compared with Day 5/day of last follow-up score; five out of 30 patients who had a pre-treatment score of 7 had shown progression and died, five had shown no improvement and remained at the same score, whereas 20 had shown improvement from their baseline score of at least one point (p-value<0.001).

**Discussion**

The WHO has raised an alarm over the numbers of cases that are exponentially increasing in the lower-middle-income countries (LMICs). It is a major cause of concern, particularly since the capacities of developed countries have been overwhelmed. Since the development of a vaccine is unlikely in the near future, the focus has been on treatment and the compassionate use of certain medications. Tocilizumab is a monoclonal antibody targeting the receptor of IL-6; a pro-inflammatory cytokine involved in the pathogenesis of ARDS seen with COVID-19 [8]. Data are urgently needed from developing countries, as a "one-size fits all" strategy cannot be used in resource-constrained regions where healthcare capacities are already overstretched [15]. Moreover, whether tocilizumab is a cost-effective option in developing countries also requires exploration because of the differences in case fatality rates from the different parts of the world suggesting that the same approaches may not be regionally relevant. We conducted an observational study describing patient outcomes in those critically ill patients of COVID-19 who received tocilizumab intravenously for hyperinflammation and ARDS. Most of the data regarding its off-label use in COVID-19 has been from studies conducted in China and parts of Europe (Table 2). The age and gender distribution of our patient population were similar to those reported in studies from China and Italy [10,16]. The mortality data has been conflicting from Italy with Colaneri et al. reporting no benefit [10], whereas Sciascia et al. showed reduced mortality in those who received treatment with tocilizumab [17]. On the other hand, outcomes have been consistently reported to be good in studies from China. At the time of submission, some had not been peer-reviewed and others did not take into account concomitant treatments [9,16]. Our study
has reported a mortality of 23%, which is similar to other studies, but we also report the concomitant use of systemic steroids in 70% of the patients, which may have contributed to immunomodulation. None of the studies so far have reported nosocomial infection, Aspergillus infection, or colonization. Since IL-6 antagonism can potentially predispose to worse outcomes in infections, this is an important observation in our study and can have implications in developing countries where there is a higher incidence of MDR infections. Our study also found clinical improvement in patients who had a pre-treatment score of 5 on the WHO ordinal scale, i.e., hospitalized with non-invasive ventilation or oxygen support, and none to minimal improvement in patients who had pre-treatment of 7, i.e. on ventilation and additional organ support, including vasopressors and renal replacement therapy. Ruiz et al. reported improvement post-tocilizumab using the ordinal scale over a longer follow-up period of 14 days in a single-center observational study [18]. Another study showed a better outcome in patients requiring mechanical ventilation with the use of tocilizumab, which is in contrast to our findings [19]. On the other hand, preliminary findings from the COVACTA trial have not shown promising results but have been criticized, as they included patients with greater severity of illness despite data from observational studies suggesting better outcomes in earlier disease and outcome assessment at one specified day, which may not account for individual differences in patients and concomitant treatment-related information, particularly systemic steroids, was not sufficient [11]. Although our study is limited because of the small sample size, lack of a comparator group, and single-center design, this is expected given the availability and cost of tocilizumab in a developing country, which makes it imperative to understand its potential for use in our setting. All the studies exploring outcomes with tocilizumab are limited due to their small sample sizes and observational design highlighting the need for randomized controlled trials. However, given the rapidity of the spread of COVID-19 infection, real-time data is needed, particularly from LMICs, which are experiencing an exponential increase in the number of cases. Our study has taken into account the fact that the peak effect of tocilizumab may be prolonged and earlier outcomes have more relevance in view of the acuteness of presentation and rapid progression in the absence of immunomodulation in patients with hyperinflammation and ARDS. Hence, the appropriate timing of tocilizumab is perhaps a key factor for improving survival [20].

| Study                 | Country of study | Number of patients who received IV TOCILIZUMAB | Study design            | Outcomes                                                                 | Conclusion                                                                 |
|----------------------|------------------|-----------------------------------------------|-------------------------|--------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Luo P et al. [16]    | China            | 15                                            | Observational           | 3/5 (20%) mortality, 2/15 with disease aggravation                      | Good response in patients with tocilizumab                               |
| Colaneri M et al. [10]| Italy            | 21                                            | Observational           | 5/21 (24%) Day-7 mortality on Day 7. No difference compared with those who didn’t get tocilizumab | Tocilizumab administration did not reduce ICU admission and mortality rate |
| Sciascia S et al. [17]| Italy            | 34                                            | Pilot prospective open single-arm | 4/31 (12%) mortality in the tocilizumab arm                             | May benefit in severe disease                                             |
| Xu X et al. [21]     | China            | 21                                            | Observational           | No mortality                                                            | Good outcome                                                              |
| Van Kraaij et al. [22]| Netherlands     | 1                                             | Case report             | Survived                                                                | Good outcome                                                              |
| Klöpfeinstein T et al. [23]| France   | 20                                            | Case-control            | 25% mortality in the tocilizumab group versus 48% in the no tocilizumab group | Good outcome                                                              |

TABLE 2: Summary of studies describing experience with tocilizumab use in severe COVID-19 infections

Conclusions

In conclusion, our study supports the use of tocilizumab in COVID-19 ARDS patients with a pre-treatment median WHO ordinal severity score of 5 (on oxygen support or NIV), whereas they may not benefit in terms of clinical outcomes if it is administered at a score of 7 (on mechanical ventilation and organ support). We also recommend the monitoring of patients who receive the medication for nosocomial and opportunistic infections, which may lead to adverse outcomes in COVID-19 patients. Furthermore, in view of issues with the COVACTA trial; a multicountry randomized controlled pragmatic trial is needed, which takes into
account the time factor in outcome assessment and differences in standard of care practiced in different regions in the setting of the pandemic.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. Aga Khan University Ethics Review Committee issued approval ERC reference number: 2020-3650-10382. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Mahase E: Covid-19: WHO declares pandemic because of 'alarming levels' of spread, severity, and inaction . BMJ, 2020, 368:m1056. 10.1136/bmj.m1056
2. COVID-19 coronavirus pandemic. (2020). https://www.worldometers.info/coronavirus/.
3. Moore JB, June CH: Cytokine release syndrome in severe COVID-19. Science. 2020, 368:473-474. 10.1126/science.abb8925
4. Qin C, Zhou L, Hu Z, et al.: Dyregulation of immune response in patients with COVID-19 in Wuhan, China . Clin Infect Dis. 2020, 71:762-768. 10.1093/cid/ctaa248
5. Chen C, Zhang X, Ju Z, He W: Advances in the research of cytokine storm mechanism induction caused by coronavirus disease 2019 and the corresponding immuno-therapies [Article in Chinese]. Zhonghua Shao Shang Za Zhi. 2020, 36:0015. 10.1373/rcma.jsr.001120-20200224-00088
6. Cavalli G, De Luca G, Campochiaro C, et al.: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020, 2:ES25-ES33. 10.1016/j.eclinm.2020.102537
7. McGonagle D, Sharif K, O Regan A, Bridgewood C: The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Antimicrob Agents. 2020, 19:102577. 10.1016/j.aant.2020.102577
8. Sanders JM, Monogue ML, Jodkowski TZ, Cutrell JB: Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020, 325:1824-1836. 10.1001/jama.2020.6019
9. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ: The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (Il-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020, 55:105954. 10.1016/j.ijantimicag.2020.105954
10. Colaneri M, Boglilo L, Valsecchi P, et al.: Tocilizumab for treatment of severe covid-19 patients: preliminary results from SMACore COVID19 Registry (SMACORE). Microorganisms. 2020, 8:695. 10.3390/microorganisms8050695
11. Furlow B: COVACTA trial raises questions about tocilizumab’s benefit in COVID-19. Lancet Rheumatol. 2020, 2:E592. 10.1016/S2665-9913(20)30515-1
12. Nasir N, Mahamood SF, Habib K, Khamnou I, Jamil B: Treatment of ARDS and hyperinflammation in COVID-19 with IL-6 antagonist tocilizumab: a tertiary care experience from Pakistan [PREPRINT]. medRxiv. 2020, 2020.1110.2023472
13. WHO: Interim guidance: Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. (2020). Accessed: July 5, 2020: https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf?
14. WHO: Clinical management of COVID-19: interim guidance. (2020). Accessed: May 27, 2020: https://www.who.int/publications/i/item/clinical-management-of-covid-19
15. The Lancet Infectious Diseases: COVID-19: endgames. Lancet Infect Dis. 2020, 20:511. 10.1016/S1473-3099(20)30298-X
16. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li L: Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020, 92:814-818. 10.1002/jmv.25801
17. Sciaccia S, Apra F, Baffa A, et al.: Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol. 2020, 38:529-532.
18. Fernández-Ruiz M, López-Medrano F, Pérez-Jacobi Asín MA, et al.: Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: a single-center cohort study. J Med Virol. 2020, [Epub ahead of print]. 10.1002/jmv.26308
19. Kewan T, Covut F, Al-Jagheer MJ, Rose L, Gopalakrishna KV, Akbik B: Tocilizumab for treatment of patients with severe COVID-19: a retrospective cohort study. EClinicalMedicine. 2020, 20:100418. 10.1016/j.eclim.2020.100418
20. Keske Ş, Tekin S, Sait B, et al.: Appropriate use of tocilizumab in COVID-19 infection. Int J Infect Dis. 2020, 99:338-345. 10.1016/j.ijid.2020.07.056
21. Xu X, Han M, Li T, et al.: Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020, 117:10970-10975. 10.1073/pnas.2005615117
22. van Kraaij TD, Mostard RL, Ramiro S, et al.: Tocilizumab in severe COVID-19 pneumonia and concomitant cytokine release syndrome. Eur J Case Rep Intern Med. 2020, 7:001675. 10.12890/2020.001675
23. Sopfenstein T, Zayer S, Lohse A, et al.: Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect. 2020, 50:397-400. 10.1016/j.medmal.2020.05.001